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Abstract
The neurobiological mechanisms underlying the association between cannabis use and acute or long-lasting psychosis are not
completely understood. While some evidence suggests altered striatal dopamine may underlie the association, direct evidence
that cannabis use affects either acute or chronic striatal dopamine is inconclusive. In contrast, pre-clinical research suggests that
cannabis may affect dopamine via modulation of glutamate signaling. A double-blind, randomized, placebo-controlled,
crossover design was used to investigate whether altered striatal glutamate, as measured using proton magnetic resonance
spectroscopy, underlies the acute psychotomimetic effects of intravenously administered delta-9-tetrahydrocannabinol (Δ9-THC;
1.19mg/2ml), the key psychoactive ingredient in cannabis, in a set of 16 healthy participants (7 males) with modest previous
cannabis exposure. Compared to placebo, acute administration of Δ9-THC signiﬁcantly increased Glutamate (Glu)+Glutamine
(Gln) metabolites (Glx) in the left caudate head (P= 0.027). Furthermore, compared to individuals who were not sensitive to the
psychotomimetic effects of Δ9-THC, individuals who developed transient psychotic-like symptoms (~70% of the sample) had
signiﬁcantly lower baseline Glx (placebo; P 7= 0.023) and a 2.27-times higher increase following Δ9-THC administration.
Lower baseline Glx values (r=−0.55; P= 0.026) and higher previous cannabis exposure (r= 0.52; P= 0.040) were associated
with a higher Δ9-THC-induced Glx increase. These results suggest that an increase in striatal glutamate levels may underlie
acute cannabis-induced psychosis while lower baseline levels may be a marker of greater sensitivity to its acute psychotomimetic
effects and may have important public health implications.
Introduction
Cannabis is the most widely used illicit drug in Europe and
over the world, with approximately 200 million users [1]
and an estimated 13 million individuals with cannabis
dependence [2]. It represents a public health concern as
cannabis use can induce transient psychotic symptoms
[3–5] and trigger the onset of psychosis in vulnerable
individuals [6]. Moreover, cannabis use can exacerbate
psychotic symptoms [7–9] and increase the risk of relapse
[10–12] in patients with established psychosis in a dose-
dependent manner [13].
Cannabis exerts its psychotomimetic effects
primarily through its psychoactive component delta-9-
tetrahydrocannabinol (Δ9-THC) [14–16]. Δ9-THC is a
partial agonist at the endocannabinoid receptor type 1
(CB1), which is widely expressed throughout the brain
[17] and downregulated in response to sustained cannabis
use [18]. Δ9-THC has consistently been shown to stimu-
late the neuronal ﬁring of mesolimbic dopamine neurons
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and elevate striatal dopamine levels in animal models
[19]. However, acute administration of Δ9-THC has
been shown to induce striatal dopamine release in some
[20–22] but not all human studies [23, 24] (also reviewed
in [25]), while a deﬁcit in striatal dopamine release has
been reported in cannabis dependence [26]. Additional
evidence suggests that Δ9-THC disrupts striatal function
[27], and genetic variation in dopamine signaling mod-
ulates this effect [16].
The difﬁculty in capturing the acute effect of Δ9-THC on
striatal dopamine in man may be explained by the biological
distance between Δ9-THC effects and dopamine dysregu-
lation, as evidence suggests that Δ9-THC does not affect
dopamine release directly but via CB1-dependent modula-
tion of glutamate signaling [17]. Converging evidence from
preclinical studies indicates that acute Δ9-THC adminis-
tration induces a dose-dependent increase in cortical extra-
cellular, striatal, and hippocampal intracellular glutamate
levels through the activation of CB1 receptors at glutama-
tergic presynapses in cortical and subcortical brain regions,
reﬂecting a reduction in synaptic glutamate levels and
receptor functioning [28–30], also reviewed here [31]. A
limited number of studies consistently support the evidence
for altered brain glutamate levels as measured by proton
magnetic resonance spectroscopy (1H-MRS) in otherwise
healthy chronic cannabis users, with all [32–35] but one
[36] of the ﬁve studies indicating reduced levels of
glutamate-derived metabolites Glutamate (Glu) or Gluta-
mate+Glutamine (Glx) in both cortical and subcortical
brain areas. The only study not showing an effect of can-
nabis on glutamate in man investigated a modestly sized
sample of cannabis users with concurrent methamphetamine
use [36]. In contrast, another study conducted in a larger
sample suggested reduced Glx metabolite concentration
also in individuals with a history of other illicit drug use
[37]. However, the cross-sectional case-control design of
these studies does not allow one to infer a cause–effect
relationship underlying the observed association between
cannabis use and glutamatergic alterations in the brain.
To our knowledge, no study has as yet investigated the
acute effect of Δ9-THC on brain glutamate levels in man as
a potential mechanism underlying its psychotomimetic
effects. Therefore, we employed a placebo-controlled acute
pharmacological challenge design to investigate the acute
effect of Δ9-THC administration on brain glutamate levels
in man. We focused on three brain regions, the striatum, the
hippocampus, and the anterior cingulate cortex (ACC), as
preclinical studies suggested that acute Δ9-THC adminis-
tration increased glutamate levels not only in the striatum
but also in other brain regions, such as the prefrontal cortex
and hippocampus [28–30].
Evidence suggests that (1) Δ9-THC administration in
animal models increases glutamate levels in the striatum
[30], (2) Δ9-THC-induced increase in glutamate levels
leads to an excess striatal dopamine via neuronal circuitry
involving hypofunctioning N-methyl-D-aspartate (NMDA)
receptors [28], and (3) Δ9-THC-induced modulation of
striatal activation is related to the severity of acute psy-
chotomimetic effects induced by it in humans [15, 16, 27].
Hence, we speciﬁcally hypothesized that (1) acute Δ9-THC
administration would be associated with an increase in
striatal glutamate-derived metabolites; (2) Δ9-THC-induced
striatal glutamate increase would be associated with the
development of psychotomimetic symptoms. Based on the
limited evidence of a blunted effect of acute Δ9-THC
administration on neurochemical markers (brain-derived
neurotrophic factor (BDNF)) in cannabis users compared to
healthy subjects [38], the following hypothesis was also
tested: (3) previous cannabis exposure would modulate the
acute effect of Δ9-THC on striatal glutamate. We also car-
ried out exploratory analyses to examine whether the acute
effects of Δ9-THC on brain glutamate levels in man were
speciﬁc to the striatum or also noted in the hippocampus
and ACC.
Methods
A detailed description of the experimental procedure, psy-
chopathological assessment, image acquisition, 1H-MRS
quantiﬁcation, and statistical analyses is provided in Sup-
plementary Methods and is summarized here brieﬂy.
We employed a double-blind, randomized, placebo-
controlled, crossover design, with counterbalanced order of
drug administration, using an established protocol [16, 39].
Sixteen right-handed healthy participants (7 males), absti-
nent from cannabis for at least 6 months and with no history
of alcohol abuse, nicotine dependence, or illicit drug use,
were assessed on two different occasions separated by at
least a 2-week interval, with each session preceded by
intravenous administration of Δ9-THC (1.19 mg/2 ml) or
saline. A power analysis indicated that a total sample of 16
people would allow detection of a medium effect (d= 0.65)
with 80% power using a one-tailed paired t-test.
Immediately before and at 20 min and 2.5 h after drug
administration, psychopathological ratings [40–43] were
recorded by an expert clinical researcher.
1H-MRS spectra (Point RESolved Spectroscopy—
PRESS; TE= 30 ms; TR= 3000 ms; 96 averages) were
acquired on a 3 Tesla MR system in the left caudate head,
ACC, and hippocampus (Fig. 1), employing the standard
GE probe (proton brain examination) sequence, which uses
a standardized chemically selective suppression (CHESS)
water suppression routine [44] that has been employed
before at this centre [45–47]. Data were analyzed with
LCModel version 6.3-1L [48].
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Data was normally distributed. Paired t-tests were used to
estimate the effects of Δ9-THC on symptoms (focusing on
peak changes from the baseline, as we did not expect
symptom manifestation by the 2.5-h time point [14]) and
striatal Glx values, and t-tests to compare Δ9-THC-induced
Glx changes between subjects sensitive to and those not
sensitive to the psychotomimetic effects of Δ9-THC, based
on the manifestation of clearly detectable primary symp-
toms of psychosis (≥2-point increase in Positive and
Negative Syndrome Scale (PANSS) [40] delusions, hallu-
cinations, unusual thought content, suspiciousness, and
grandiosity items), as drawn from previous factor analytic
work [49] as well as previous work to characterize acute
sensitivity to Δ9-THC [50]. Pearson correlation analyses
were used to test for an association between changes in
striatal Glx values and previous cannabis exposure (SPSS
version 22; SPSS Inc., Chicago, IL).
The composite Glx peak has been widely used as a
marker of glutamatergic function, because it likely pre-
dominantly reﬂects glutamate levels, which are typically
5–6 times higher than those of glutamine [51]. Many of the
functions of glutamine are connected to the formation of
glutamate and the glutamate/glutamine cycle has to be seen
as a bi-directional cycle involved in key aspects of
metabolism and synaptic function [52]. Research evidence
suggests a close coupling of overall neuronal activity and
glutamate–glutamine ﬂuxes, with cortical synaptic gluta-
mate release and glutamate–glutamine cycling consuming
approximately 60–80% of the energy produced by oxidative
metabolism of glucose. This evidence suggests that synaptic
glutamate–glutamine cycling cannot be differentiated from
overall glutamate metabolism [53]. Therefore, Glx, the main
outcome measure of the MRS study presented here, reﬂects
the total glutamatergic pool available for synaptic/metabolic
activity [54].
Results
Demographic variables, physiological measures, and
whole-blood Δ9-THC levels
Study participants had a mean age of 24.44 years (SD:
4.29). They had a mean of 16.94 (SD: 2.84) years of
education.
Placebo administration had no effect on systolic (mmHg,
M ± SD; baseline: 117.31 ± 13.26; drug: 118.56 ± 9.75; P >
0.1) and diastolic blood pressure (baseline: 62.5 ± 9.32;
Fig. 1 1H-MRS data acquisition. 1H-MRS, proton magnetic resonance spectroscopy. a Left anterior cingulate cortex (ACC), b left hippocampus,
and c left head of the caudate
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drug: 66.38 ± 10.56; P > 0.05), and heart rate (beats per
minute; baseline: 69.44 ± 13.28; drug: 70.94 ± 13.90, P >
0.1). Δ9-THC administration had no effect on systolic
(baseline: 117.13 ± 10.35; drug: 117.81 ± 11.78; P > 0.1)
and diastolic blood pressure (baseline: 64.25 ± 9.28; drug:
66.13 ± 7.05; P > 0.1) but a signiﬁcant effect on heart
rate (baseline: 68.69 ± 12.72; drug: 89.31 ± 22.57, t= 4.65,
P < 0.001).
The Δ9-THC plasma levels (M ± SE; gas chromatography–
mass spectrometry, GC–MS) reached a peak 20min after drug
administration (220.2 ± 34.1 ng/mL), and then began to fall
(2.5 h after drug administration: 54.6 ± 8.6 ng/mL).
Acute effect of Δ9-THC on psychopathological
measures
As expected, administration of Δ9-THC was associated
with acute induction of transient psychotic symptoms
(PANSS positive symptoms subscale, t= 6.62, P < 0.001;
PANSS negative symptoms subscale, t= 4.95, P < 0.001;
PANSS general symptoms subscale, t= 6.85, P < 0.001;
PANSS total score, t= 6.77, P < 0.001). Also, Δ9-THC
induced an acute and transient increase in symptoms of
anxiety (STAI scale, t= 3.72, P= 0.002). Finally, subjects
experienced signiﬁcant Δ9-THC-induced intoxication (AIS,
t= 9.41, P < 0.001) and sedation (VAMS mental sedation
subscale, t= 7.72, P < 0.001; VAMS physical sedation
subscale, t= 4.90, P < 0.001; Fig. 2). Eleven subjects (69%)
were identiﬁed as sensitive to the psychotomimetic effects
of Δ9-THC as determined on the basis of ≥2-point increase
in the relevant PANSS items (as described in Methods)
[49]. They had a 5.91 (±4.18) point increase in the primary
symptoms of psychosis compared to a 0.6 point increase
(±0.55) for the remaining subjects (drug effect, t= 4.13,
P= 0.002).
1H-MRS results
Voxel segmentation and spectral quality are reported in
Table 1.
Striatal Glx measures
As hypothesized, acute Δ9-THC administration increased
Glutamate (Glu)+Glutamine (Gln) metabolites (Glx) in the
left caudate head (placebo: 10.03 ± 2.25; Δ9-THC: 12.22 ±
3.49; t= 2.09, P= 0.027; effect size: 0.75; Fig. 3). There
was an inverse relationship between baseline Glx values (as
measured under the placebo condition) and change in Glx
induced by acute Δ9-THC administration. This was such
that, the lower the Glx values under placebo, the higher was
the increase following Δ9-THC administration (r=−0.55;
P= 0.026). Furthermore, there was a positive correlation
between previous cannabis exposure (as indexed using
lifetime number of times of cannabis use) and Δ9-THC-
induced increase in Glx (drug effect, r= 0.52; P= 0.040).
Glx values under the placebo condition were sig-
niﬁcantly lower in subjects who were sensitive to Δ9-THC-
induced psychotomimetic effects (9.20 ± 1.93) compared to
subjects who were not (11.85 ± 1.93; t= 2.54, P= 0.023).
Following acute Δ9-THC administration, compared to
subjects who were not sensitive to the psychotomimetic
Fig. 2 Acute effect of Δ9-THC on psychopathological measures. THC
(−)-trans-Δ9-tetrahydrocannabinol, PLB placebo, PANSS Positive and
Negative Syndrome Scale, STAI State-Trait Anxiety Inventory, AIS
Analog Intoxication Scale, VAMS Visual Analog Mood Scale, mins
minutes, h hours, P 2-tailed; error bars show standard deviations
M. Colizzi et al.
effects (13.01 ± 3.02), subjects sensitive to the psychoto-
mimetic effects of Δ9-THC had a 2.27-times higher increase
in Glx values (11.85 ± 3.76). However, this difference failed
to reach signiﬁcance (P > 0.1; Fig. 4).
Acute Δ9-THC administration had no effect on ACC
(placebo: 19.47 ± 3.04; Δ9-THC: 20.11 ± 2.04) and hippo-
campal Glx (placebo: 11.74 ± 2.32; Δ9-THC: 12.29 ± 2.30;
all P > 0.1). Other metabolite levels are reported in Sup-
plementary Table 1.
Discussion
This is the ﬁrst human study to investigate the acute effect of
intravenous Δ9-THC administration on brain glutamate
levels, and whether glutamate level alterations underlie the
acute psychotomimetic effects of Δ9-THC. Consistent with
our ﬁrst hypothesis and with previous evidence from animal
studies [28–31] we found that acute administration of Δ9-
THC signiﬁcantly increased Glx levels in the left caudate
head compared to the placebo. As predicted, we also found
that this was associated with transient psychotomimetic
effects induced by Δ9-THC. Our most novel ﬁnding is that
individuals who experienced transient psychotomimetic
effects following Δ9-THC (~70% of the sample) had sig-
niﬁcantly lower baseline Glx (as under placebo) and an
almost two-and-a-half-fold higher increase in Glx following
Δ9-THC administration compared to individuals who were
Table 1 Voxel segmentation and spectral quality
Brain region Δ9-THC PLB Statistics
Parameter M (SD) M (SD) t P value
Left caudate head
Cramér–Rao lower bound
Glu 9.25 (2.35) 9.00 (1.83) 0.37 0.71
Glx 11.12 (3.54) 10.87 (2.58) 0.24 0.81
NAA+ NAAG 3.62 (1.15) 3.19 (0.54) 1.52 0.15
Cr 3.37 (0.62) 3.50 (0.89) −0.56 0.58
mI 8.07 (3.47) 9.67 (4.67) −1.50 0.15
GPC+ PCh 4.31 (0.79) 4.44 (1.46) −0.34 0.74
Full width at half maximum 0.07 (0.01) 0.06 (0.01) 1.91 0.08
Signal to noise ratio 16.50 (3.92) 17.88 (3.69) −1.14 0.27
Grey matter (%) 48.77 (7.05) 49.32 (5.65) −0.28 0.78
White matter (%) 49.40 (7.26) 48.84 (6.73) 0.31 0.76
Cerebrospinal ﬂuid (%) 1.81 (1.86) 1.80 (1.79) 0.02 0.99
Left anterior cingulate cortex
Cramér–Rao lower bound
Glu 5.69 (0.79) 5.94 (1.06) −0.77 0.45
Glx 6.31 (0.87) 6.75 (1.06) −1.81 0.09
NAA+ NAAG 2.69 (0.48) 2.69 (0.60) 0.00 1.00
Cr 2.75 (0.45) 2.62 (0.62) 0.70 0.50
mI 4.69 (0.60) 5.12 (1.89) −0.92 0.37
GPC+ PCh 3.25 (0.58) 3.25 (0.45) 0.00 1.00
Full width at half maximum 0.04 (0.01) 0.03 (0.01) 1.78 0.10
Signal to noise ratio 24.56 (5.20) 25.44 (5.50) −0.61 0.55
Grey matter (%) 67.64 (4.43) 67.06 (5.14) 0.94 0.36
White matter (%) 10.94 (2.59) 11.85 (2.46) −1.59 0.13
Cerebrospinal ﬂuid (%) 21.26 (5.36) 20.94 (5.36) 0.45 0.66
Left hippocampus
Cramér–Rao lower bound
Glu 9.87 (1.82) 9.94 (2.52) −0.10 0.92
Glx 9.50 (2.85) 10.31 (2.73) −0.90 0.38
NAA+ NAAG 4.00 (1.21) 4.75 (1.13) −2.16 0.05
Cr 4.06 (0.68) 4.19 (0.75) −0.81 0.43
mI 5.37 (1.09) 6.06 (1.65) −2.11 0.05
GPC+ PCh 4.06 (0.44) 4.19 (0.83) -0.62 0.54
Full width at half maximum 0.07 (0.01) 0.07 (0.01) 0.95 0.36
Signal to noise ratio 12.81 (2.14) 12.13 (2.28) 1.14 0.27
Grey matter (%) 59.86 (8.12) 60.23 (6.58) −0.20 0.85
White matter (%) 36.42 (8.96) 35.68 (7.60) 0.36 0.72
Cerebrospinal ﬂuid (%) 3.69 (1.39) 4.06 (1.56) −1.39 0.19
Δ9-THC delta-9-tetrahydrocannabinol, PLB placebo, Glu glutamate,
Glx glutamate+ glutamine, NAA+NAAG N-acetylaspartate+N-acet-
ylaspartylglutamate, Cr creatine, mI myo-inositol, GPC+ PCh
Glycerophosphocholine+ phosphocholine
Fig. 3 Acute effect of Δ9-THC on glutamate measures in the left head
of the caudate. THC (−)-trans-Δ9-tetrahydrocannabinol, PLB placebo,
P 1-tailed; error bars show standard deviations
Fig. 4 Acute effect of Δ9-THC on glutamate measures in the left head
of the caudate as a function of the psychotomimetic symptom
manifestation. THC (−)-trans-Δ9-tetrahydrocannabinol, PLB placebo,
P 2-tailed; error bars show standard deviations
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not sensitive to the psychotomimetic effects of Δ9-THC.
Finally, consistent with our prediction, previous cannabis
exposure was positively associated with Δ9-THC-induced
Glx increase. Exploratory analyses also suggested that the
acute effects of Δ9-THC on human brain Glx levels are
region-speciﬁc, as Δ9-THC administration increased Glx
levels in the striatum, but not in the hippocampus or the ACC.
In addition to the brain stem projections, the key inputs
to the striatum are mesolimbic dopaminergic (DA) projec-
tions from the ventral tegmental area (VTA) as well as
cortical and thalamic glutamatergic projections [55, 56].
The activity of VTA DA neurons in vivo is dominated by
pacemaker-like tonic ﬁring interrupted by phasic bursts
leading to striatal dopamine release [57], and this shift from
tonic pacemaker ﬁring to bursting is strongly controlled by
synaptic input from glutamatergic and GABAergic afferents
to the dopamine neurons [58]. Upon acute exposure,
endocannabinoids regulate synaptic strength by acting on
glutamatergic afferents to VTA dopamine neurons via
activation of CB1 receptors [59]. Preclinical evidence also
indicates that the intravenous administration of Δ9-THC
can increase VTA dopamine neuronal activity, being ulti-
mately responsible for an increase in striatal dopamine
levels through the mesolimbic pathway [19]. However,
in vitro studies have demonstrated that cannabinoids do not
affect dopamine concentrations when locally applied in the
striatum [60], while increasing dopaminergic ﬁring when
administered in the VTA [61]. Since VTA dopamine neu-
rons do not express CB1 receptor protein nor mRNA [62],
this argues against a direct effect of cannabinoids on
dopamine neuron activity, also potentially accounting for
the inconsistent evidence on effects of Δ9-THC adminis-
tration on striatal dopamine release in man [20–25]. In
contrast, the glutamatergic inputs to the striatum are espe-
cially relevant as they are involved in the processing of
different stimuli, such as rewarding and stressful informa-
tion, and the selection of related behavioral responses [63].
In line with this, acute Δ9-THC administration in animal
models has been shown to consistently increase glutamate
levels in a number of brain regions including the striatum
[28–31]. Therefore, glutamate rather than dopamine may
play a more important role in the neurochemical under-
pinnings of the acute psychotomimetic effects of cannabis
[31]. However, no acute challenge study had investigated
the effect of acute administration of Δ9-THC on glutamate
metabolism in humans. In sum, our study conﬁrms pre-
clinical evidence [28–31] that a single dose of Δ9-THC may
increase striatal glutamate levels and suggests this as a
potential mechanism underlying the acute psychotomimetic
effects of cannabis.
Previous preclinical research indicates that a history of
psychostimulant self-administration leads to decreased basal
glutamate in both the striatum and the primary neuronal
source of striatal glutamate, the prefrontal cortex. Instead,
acute psychostimulant drug administration in abstinent
animal models previously exposed to the drug induces an
enhancement of cortical and striatal glutamate release not
seen in drug-naive subjects [64, 65]. Drug-induced heigh-
tened activation of cortical glutamatergic afferents to the
VTA has been proposed to modulate behavioral sensitiza-
tion and addiction [66]. In line with this evidence, we found
that the lower the striatal Glx levels at baseline, the higher
was the increase after Δ9-THC administration. Furthermore,
we found that the higher the previous cannabis exposure,
the higher was the Δ9-THC-induced striatal increase,
potentially suggesting sensitization due to the effects of
previous cannabis exposure. However, an important caveat
to such an interpretation is the relatively modest levels of
previous cannabis use (1 ≤ previous use ≤60 times, 10.4 ±
14.4 times on average). Nevertheless, sensitization (if it is
present) to such low levels of exposure is not surprising as
preclinical evidence suggests that even a single exposure to
psychostimulant drugs can be sufﬁcient to induce long-
lasting behavioral and cellular sensitization [66]. One may
therefore speculate that the glutamatergic system may have
a different steady-state homeostasis as a function of pre-
vious exposure, from where the system is particularly sus-
ceptible to destabilizing inﬂuences that may affect it, such
as the acute administration of Δ9-THC. As lower baseline
Glx levels and related higher Δ9-THC-induced increase
were evident in individuals who developed psychotomi-
metic symptoms under Δ9-THC compared to individuals
who did not, our ﬁndings suggest that Δ9-THC-induced
psychotomimetic symptoms could be explained by Δ9-THC
effects on tonic (basal) versus phasic (burst) glutamate
system function, which in turn are modulated by previous
cannabis use.
ACC and hippocampal Glx were not signiﬁcantly
increased by acute Δ9-THC administration, suggesting that
glutamate alteration in the striatum may represent a speciﬁc
locus of abnormality underlying sensitivity to the acute and
transient psychotomimetic effects of Δ9-THC. However,
this needs to be conﬁrmed in larger samples.
Glutamate steady-state homeostasis and sensitization may
also account for the apparent discrepancy between the
reduction in glutamate observed in studies of chronic cannabis
use in man [32–35, 37] and the increase in glutamate
observed in preclinical acute challenge studies [28–31] as
well as in the present acute challenge study in humans.
Animal studies of chronic psychostimulant use clearly indi-
cate drug-induced changes in glutamate regulation, such that
basal glutamate levels are decreased while glutamate release
is enhanced during drug exposure [64, 65]. Cannabis use may
involve progressive neurochemical adaptations in glutamate
function, which need to be further investigated. Determining
the regional changes in glutamate function that may result
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from repeated cannabis exposure is also imperative to
understanding their relevance to the acute and chronic psy-
choactive effects of cannabis use. To date, there is robust
evidence for altered glutamate steady-state homeostasis in
animal models of addiction [64, 65]. However, aberrant glu-
tamate function has also been suggested in psychosis and
related disorders. In particular, a systematic review of 63 stu-
dies investigating metabolite biomarkers of schizophrenia has
indicated glutamate increase as one of the most consistent
potential metabolite signatures of the disorder [67]. Increased
striatal glutamate levels have also been described in subjects
at ultra-high risk for psychosis, and they are also associated
with conversion to psychosis [68, 69].
The major strength of this study is its design. Study
subjects were recruited if they had a minimal history of
cannabis use, had been abstinent from cannabis for at least
6 months, and had negligible use of other substances
(alcohol, tobacco, and other illicit drugs). Therefore, we can
reasonably rule out the possibility that some of the results
observed could be attributed to the effects of other sub-
stance use or cannabis withdrawal, dependence, or intox-
ication. Moreover, for each study participant, there was an
interval of at least 14 days between the two study visits.
This helps exclude the possibility of any carryover effects as
Δ9-THC has been shown to have an elimination half-life of
18 h to 4.3 days [70]. Also, all the participants’ urine
samples collected at each study visit at baseline were
negative for the presence of Δ9-THC. However, these strict
inclusion criteria, while offering advantages in terms of a
controlled sample, may at the same time limit the general-
izability of the present results to the wider population of
cannabis users. Also, the intravenous route for Δ9-THC
administration allowed much more consistent Δ9-THC
blood levels across study subjects [14], but might have
similarly affected the generalizability of the results to the
effects of recreational cannabis use. Another limitation of
the present study is that, due to its design, it was not pos-
sible to examine the test–retest reliability of the MRS Glx
measure for the regions investigated. However, evidence
indicates that GM Glx in healthy subjects has relatively
high reproducibility and test–retest reliability at 3 Tesla
[71]. Furthermore, the within-subject design helped avoid
the confounding effect of between-subject differences in the
outcome variable [71].
It is worth noting that 1H-MRS does not allow us to
disentangle whether measured glutamate is from the neu-
rotransmitter or the metabolic pool. Nevertheless, research
evidence indicates that majority of the brain glutamate
is cycled through the neurotransmitter pool [53] and
1H-MRS-related glutamate measures are likely to be related
to glutamatergic neurotransmission [54].
It is worth considering a few other potential alternative
explanations for the results presented here, such as effect of
spectral quality differences, effect of T2 relaxation and test–
retest effect. Cramér–Rao lower-bound values were con-
siderably below the 20% threshold under both drug condi-
tions. Although full width at half maximum (FWHM)
values showed a trend toward difference between the two
drug conditions, they were also within the spectral quality
recommended by Kreis (FWHM of metabolites < 0.07–0.1
ppm) [72]. Collectively, they suggest good quality data, and
are more informative than a comparison of quality measures
across the drug conditions (Δ9-THC, placebo) [72]. Results
presented here also point toward regional speciﬁcity of the
acute effects of THC, as no effects on any metabolite were
observed in the hippocampus and anterior cingulate,
arguing against these effects being a result of spectral
quality differences.
With reference to the possibility that a T2 relaxation
effect might have occurred, decreasing the signal, this is
expected to happen when a longer echo time (TE) is used
[73]. Instead, the combination of a short TE and a long
repetition time (TR) used in this study is considered to
allow the acquisition of signals with minimal signal loss due
to T2- and T1-weighting [73]. Nevertheless, the T2
relaxation of water, which differs between white matter,
grey matter, and CSF may be different between individuals
because of the presence of different fractions of these
components in the MRS voxel, and arguably may introduce
a systematic bias in metabolite quantiﬁcation due to group
difference in T2 relaxation. However, this is unlikely to
have systematically affected the results of the present study
as we employed a within-subject repeated measures design,
thereby mitigating the effect of group difference in the
fraction of grey matter, white matter, and CSF in the MRS
voxel contributing to difference in T2 relaxation under the
two drug conditions (Δ9-THC versus Placebo). Further-
more, the randomized crossover design with counter-
balanced order of drug administration employed in this
study also helped mitigate a possible test–retest effect.
In summary, this study suggests that striatal glutamate
levels are increased following a single dose of Δ9-THC in
healthy individuals. This Δ9-THC-induced glutamate
increase likely underlies the acute cannabis-induced psy-
chotomimetic effects, as it seems to be speciﬁc to subjects
experiencing psychotomimetic effects. These results also
suggest that lower baseline levels of striatal glutamate may
be a marker of sensitivity to the acute psychotomimetic
effects of cannabis and potential sensitization to the mod-
ulation of striatal glutamate levels by Δ9-THC as a function
of previous cannabis exposure may develop early. Collec-
tively, these results provide novel insight into the neuro-
chemical underpinnings of the effects of cannabis in man
and may point towards potential approaches towards miti-
gating the adverse effects of cannabis, which may have
important public health implications.
Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications. . .
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